Advisors
Michael S. Conte, M.D.
Bradley S. Dixon, M.D.
Elazer Edelman, M.D., Ph.D.
Marc Glickman, M.D.
Jeffrey H. Lawson, M.D., Ph.D.
Prabir Roy-Chaudhury, M.D., Ph.D.
Mohamed H. Sayegh, M.D.
A. Frederick Schild, M.D., F.A.C.S.
Joseph P. Vacanti, M.D.
Michael S. Conte, M.D.
Professor and Chief, Division of Vascular Surgery, University of California San Francisco Medical Center
Dr. Conte is Professor and Chief at the University of California San Francisco, Division of Vascular Surgery. He is a Distinguished Fellow of the Society for Vascular Surgery, Society of University Surgeons, Association for Academic Surgery, and the New England Society for Vascular Surgery. He has served on several advisory boards to biotechnology and pharmaceutical companies, and on the editorial boards of the Journal of Vascular Surgery, Vascular Medicine, Vascular and Endovascular Surgery, and Vascular.
Dr. Conte is a vascular surgeon-scientist whose translational research program has encompassed the range from basic laboratory investigations to large multi-center clinical trials. His research has focused on control of the vascular injury response, using cellular and genetic approaches, with a goal of improving the long-term results of vascular grafts and interventional procedures. Dr. Conte served as Lead Investigator of the recently completed PREVENT III trial, a multi-center, Phase 3 study of an oligonucleotide therapy for peripheral vein bypass grafts. He has an active clinical practice in vascular surgery, including complex limb revascularization, aortic and carotid artery surgery, and hemodialysis access.
Bradley S. Dixon M.D.
Associate Professor of Medicine, Roy and Lucille Carver School of Medicine, University of Iowa
Dr. Dixon is an Associate Professor of Medicine at the University of Iowa Roy and Lucille Carver School of Medicine and a staff physician at the Iowa City Veterans Affairs Medical Center. He is a member of the American Society of Nephrology, American Heart Association, American Society of Cell Biology and American Association for the Advancement of Science, and a member of the Steering Committee of the National Institutes of Health-sponsored Dialysis Access Consortium (DAC).
Dr. Dixon has a longstanding interest in vascular biology and guides both basic and clinical research programs directed at understanding the mechanisms and control of neointimal hyperplasia. Basic research in his lab focuses on understanding the signal transduction pathways regulating vascular smooth muscle cell proliferation, and his clinical research has focused on the problem of vascular access failure in hemodialysis patients. Recent research from his group has examined the efficacy of routine access flow monitoring with prophylactic angioplasty to prolong access survival. His ongoing work is also directed at understanding the pathogenesis and treatment of impaired fistula maturation. Dr. Dixon obtained his M.D. degree from the University of Southern California and completed his Residency in Internal Medicine and Fellowship in Nephrology at the University of Colorado Health Sciences Center.
Elazer Edelman, M.D., Ph.D.
Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, Massachusetts Institute of Technology
Professor of Medicine, Harvard Medical School
Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women's Hospital in Boston. Dr. Edelman also directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. Dr. Edelman and his laboratory have pioneered basic findings in vascular biology. Work with antisense oligonucleotides, HDL receptor biology and tissue engineered endothelial implants are a few examples of novel directions taken by his laboratory. Many of his findings are now in clinical trial validation. Dr. Edelman is a fellow of, the American College of Cardiology, the American Heart Association, the American Institute for Medical and Biological Engineering, and the American Society for Clinical Investigation.
Marc Glickman, M.D.
Managing Director, Vascular and Transplant Specialists
Dr. Glickman is the Managing Director of Vascular and Transplant Specialists (formerly known as Virginia Vascular Associates) where he also serves as a member of its Board of Directors. He is certified by the American Board of Surgery in both general surgery and vascular surgery, and is a Fellow of the American College of Surgeons (FACS). Dr. Glickman also serves as the medical director for Sentara's Southside & Peninsula hospitals' vascular services. Dr. Glickman has held academic appointments at Ohio State University, Eastern Virginia Medical School, and Old Dominion University.
Dr. Glickman directs Vascular & Transplant Specialists’ amputee rehabilitation unit, as well as the group's industry-sponsored clinical research programs. He has co-authored and published numerous vascular disease and vascular surgery articles, and is a well-recognized leader in the field of vascular access. Dr. Glickman received his medical degree from Case Western Reserve University and finished his general surgery residency at the University of Washington Hospitals in Seattle, Washington. Dr. Glickman completed his vascular surgery fellowship at Saint Anthony Hospital in Columbus, Ohio.
Jeffrey H. Lawson, M.D., Ph.D.
Vascular Surgeon, Associate Professor of Surgery, Assistant Professor of Pathology, Duke University Medical Center
Dr. Lawson is an Associate Professor of Surgery and Assistant Professor of Pathology in the Departments of Surgery and Pathology at Duke University Medical Center in Durham, North Carolina. Dr. Lawson is a member of both the Thrombosis and Cardiovascular Surgery Councils of the American Heart Association. He has also received the Clinician Scientist Award from the American Heart Association and been named Research Scholar by the American College of Surgeons. The American Heart Association, the National Institutes of Health, and various biomedical corporations fund Dr. Lawson’s research.
Dr. Lawson is Director of Clinical Trials in Vascular Surgery at Duke University Medical Center, and also directs the Vascular Surgery research laboratory. Dr. Lawson’s research focuses on the protein biochemistry of blood coagulation and hemostasis. He has co-authored 70 publications and numerous abstracts on blood coagulation, surgery and hemostasis and lectures both nationally and internationally on these topics.
Prabir Roy-Chaudhury, M.D., Ph.D.
Associate Professor of Medicine, Section Chief of Transplantation, Division of Nephrology, University of Cincinnati
Dr. Roy-Chaudhury is an Associate Professor of Medicine in the Division of Nephrology at the University of Cincinnati. He is currently an active transplant nephrologist at University Hospital, Cincinnati. Dr. Roy-Chaudhury is currently the Chairman of the Medical Advisory Board of the Kidney Foundation of Greater Cincinnati and a member of the Board of Trustees of this organization. He is also a member of the Vascular Access Advisory Panel and the Medical Review Board of the Renal Network.
Dr. Roy-Chaudhury’s main research interest is in the pathogenesis and therapy of vascular stenosis and neointimal hyperplasia, especially in the setting of hemodialysis vascular access dysfunction. Dr. Roy-Chaudhury has published over 75 peer reviewed scientific papers and book chapters and has lectured extensively in this area. He graduated from the Armed Forces Medical College, Pune, India and completed his doctoral studies at the University of Aberdeen, Scotland. He received his internal medicine and nephrology training at the University of Aberdeen, Scotland and at Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts.
Mohamed H. Sayegh, M.D.
Director of the Transplantation Research Center, Brigham and Women’s Hospital, Boston
Dr. Sayegh is the Director of the Transplantation Research Center at Brigham and Women's Hospital and Children’s Hospital in Boston, Massachusetts. Additionally, he is the Warren E. Grupe and John P. Merrill Chair in Transplantation Medicine, Professor of Medicine and Pediatrics at Harvard Medical School, Associate Chief, Renal Division, Brigham and Women’s Hospital, and Research Director, Nephrology Division at Children's Hospital in Boston. Dr. Sayegh is the active co-chair of the Steering Committee of the National Institutes of Health (NIH) Immune Tolerance Network and Member of the Executive Committee. He is also chair of the Steering Committee of the NIH consortium Clinical Trials in Organ Transplantation (CTOT). Dr. Sayegh currently serves as the chair of the program committee of the 2006 World Transplant Congress and the 2007 World Congress of Nephrology.
Dr. Sayegh's research work has focused on the mechanisms of the immune response to alloantigen (allorecognition) and the mechanisms of tolerance induction in experimental models of transplantation and in humans. His research is funded by the NIH and Juvenile Diabetes Research Foundation. Dr. Sayegh received his M.D. at the American University of Beirut-Lebanon and completed his Medical Residency at the Cleveland Clinic Foundation. He had a fellowship in Nephrology, Clinical and Research, at Brigham and Women's Hospital.
A. Frederick Schild, M.D., F.A.C.S.
Professor of Surgery, Vascular Access Surgery, The DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami
Dr. Schild is a Professor of Clinical Surgery and Vascular Access Surgery at the University of Miami/Jackson Memorial Medical Center. During his years in practice, he has been President of the Dade County Medical Association, the Florida Medical Association, the Florida Chapter of the American College of Surgeons, the American Society of General Surgeons and is presently the Founding President of the Vascular Access Society of the Americas. He served on the Board of Governors for the In the American College of Surgeons for six years and presently serves on the American College of Surgeons, Advisory Council for General Surgery as well as their Health Policy Steering Committee (legislation).
Dr. Schild’s clinical and research interests focus on vascular access surgery for dialysis, spanning new materials, implants and techniques for reducing access failure. He has published many articles in peer review medical and surgical journals and has given talks all over the U.S., Europe, Asia and South Africa. Dr. Schild received his M.D. degree from the Medical University of South Carolina, Charleston, performed a rotating internship at L.A. County Hospital in Los Angeles, and completed his surgery residency at the University of Miami/Jackson Memorial Hospital serving as Chief Resident for two years.
Joseph P. Vacanti, M.D.
Chief of Pediatric Surgery, Massachusetts General Hospital
Dr. Vacanti is the Chief of Pediatric Surgery at Massachusetts General Hospital (MGH) and Surgeon-in-Chief at MassGeneral Hospital for Children. Dr. Vacanti is also the John Homans Professor of Surgery at Harvard Medical School, the Director of the Laboratory for Tissue Engineering and Organ Fabrication, Co-Director of the Center for Regenerative Medicine, MGH, and Director of Pediatric Transplantation at MassGeneral Hospital for Children. Dr. Vacanti is a member of the Institute of Medicine of the National Academy of Sciences.
Dr. Vacanti has worked in tissue engineering since the advent of the field in the early 1980s, and he has held academic appointments at Harvard Medical School since 1974. He has authored over 250 original reports, 58 book chapters, and over 400 abstracts. He has 50 patents or patents pending in the U.S., Canada, Europe, Australia, and Japan. Dr. Vacanti received his M.D. from University of Nebraska College of Medicine, and a M.S. from Harvard Medical School. He trained in General Surgery at the Massachusetts General Hospital, in Pediatric Surgery at Children's Hospital, Boston, and Transplantation at the University of Pittsburgh.